BACKGROUND: Vaginal microbicides are in development for the prevention of HIV transmission to women via sexual intercourse. Acceptability of the microbicide delivery method in the targeted population is important to product adherence and, therefore, product effectiveness. It is anticipated that multiple delivery methods will be required to satisfy personal preferences among future microbicide users. METHODS: A total of 526 sexually active women aged 18-30 years participated in a consumer product preference study in Burkina Faso, Tanzania, and Zambia. Screened women who had given consent were instructed to use each of the three products (placebo formulations of a vaginal tablet, film, and soft-gel capsule) once daily for 7 consecutive days for a total of 21 days. Women were interviewed about their impressions of the product at the completion of each 7-day trial period. RESULTS: Over 80% of women reported they liked using each dosage form, and over 85% said they would definitely use it. The film and soft-gel capsule were chosen significantly more often than the tablet as the preferred dosage form (39% and 37% vs. 25%, respectively) mainly because of faster dissolving time and easier insertion. Women in Burkina Faso and Tanzania preferred the soft-gel capsule (42%-46%), whereas Zambian women preferred the film (51%). Age, socioeconomic status, and marital status did not significantly affect product preference. CONCLUSIONS: All three dosage forms were acceptable to the women surveyed. Preferred dosage forms varied by country. These data suggest that the availability of microbicides in multiple dosage forms may increase acceptability, adherence, and, therefore, effectiveness.
BACKGROUND: Vaginal microbicides are in development for the prevention of HIV transmission to women via sexual intercourse. Acceptability of the microbicide delivery method in the targeted population is important to product adherence and, therefore, product effectiveness. It is anticipated that multiple delivery methods will be required to satisfy personal preferences among future microbicide users. METHODS: A total of 526 sexually active women aged 18-30 years participated in a consumer product preference study in Burkina Faso, Tanzania, and Zambia. Screened women who had given consent were instructed to use each of the three products (placebo formulations of a vaginal tablet, film, and soft-gel capsule) once daily for 7 consecutive days for a total of 21 days. Women were interviewed about their impressions of the product at the completion of each 7-day trial period. RESULTS: Over 80% of women reported they liked using each dosage form, and over 85% said they would definitely use it. The film and soft-gel capsule were chosen significantly more often than the tablet as the preferred dosage form (39% and 37% vs. 25%, respectively) mainly because of faster dissolving time and easier insertion. Women in Burkina Faso and Tanzania preferred the soft-gel capsule (42%-46%), whereas Zambian women preferred the film (51%). Age, socioeconomic status, and marital status did not significantly affect product preference. CONCLUSIONS: All three dosage forms were acceptable to the women surveyed. Preferred dosage forms varied by country. These data suggest that the availability of microbicides in multiple dosage forms may increase acceptability, adherence, and, therefore, effectiveness.
Authors: Elizabeth T Montgomery; Jonathan Stadler; Sarita Naidoo; Ariana W K Katz; Nicole Laborde; Morgan Garcia; Krishnaveni Reddy; Leila E Mansoor; Juliane Etima; Chifundo Zimba; Miria Chitukuta; Lydia Soto-Torres Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Toral Zaveri; Cordelia A Running; Lahari Surapaneni; Gregory R Ziegler; John E Hayes Journal: Drug Deliv Transl Res Date: 2016-10 Impact factor: 4.617
Authors: Ariane van der Straten; Elizabeth T Montgomery; Miriam Hartmann; Alexandra Minnis Journal: Curr HIV/AIDS Rep Date: 2013-03 Impact factor: 5.071
Authors: Jennifer A Robinson; Mark A Marzinke; Edward J Fuchs; Rahul P Bakshi; Hans M L Spiegel; Jenell S Coleman; Lisa C Rohan; Craig W Hendrix Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Kate M Guthrie; Joseph L Fava; Sara E Vargas; Rochelle K Rosen; Julia G Shaw; Erna M Kojic; Anthony S Ham; Lisa C Rohan; David Katz; Anacecilia Panameño; Christopher Colleran; David F Friend; Karen W Buckheit; Robert W Buckheit Journal: AIDS Res Hum Retroviruses Date: 2020-11-03 Impact factor: 2.205
Authors: Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191